Amusingly, Oppenheimer analyst Balaji Gandhi cites lower heparin pricing as a motivation for the APPX buyout by Fresenius: <a href="http://www.reuters.com/article/marketsNews/idINL0765539120080707" target="_blank">http://www.reuters.com/article/marketsNews/idINL0765539120080707</a>